| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | After FDA nod for novel Cabometyx formulation, analysts predict limited threat to Exelixis | ||
| Fr | Fierce Pharma Asia-Takeda's R&D leadership change; Daiichi's $1.3B court win; New Samsung Bio contract | ||
| Fr | CDMO Argonaut sheds life sciences, diagnostics division for undisclosed sum | ||
| 10.09. | Swiss CDMOS making moves: Lonza bets on new US facility, CordenPharma scales injectables with €80M | ||
| 10.09. | AbbVie lines up Qulipta expansion with phase 3 win in untapped menstrual migraine indication | ||
| 10.09. | Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters | ||
| 10.09. | In draft guidance, NICE rebuffs Gilead's twice-a-year PrEP med for national coverage | ||
| 10.09. | Samsung Bio, waiting to break into peptides, nets $262M manufacturing deal with unnamed EU pharma | ||
| 09.09. | FDA clears Bayer's Hyrnuo in first-line lung cancer, amping up Hernexeos rivalry | ||
| 09.09. | Actor Kevin Costner does the math in Caris Detect early cancer detection push | ||
| 09.09. | Merck trims another 54 jobs in New Jersey amid multiyear cost-cutting initiative | ||
| 09.09. | BioMarin pads case for Voxzogo expansion as achondroplasia competition field shifts | ||
| 09.09. | FDA solidifies CDER, CBER leadership posts as commissioner confirmation awaits | ||
| 08.09. | Sandoz sets sights on 100 biosimilars in new 2040 strategy, with $300M facility build | ||
| 08.09. | Eight Trends Reshaping Patient-Centric Drug Development | ||
| 08.09. | Amgen's DLL3-targeted Imdelltra scores overall survival win in first-line small cell lung cancer | ||
| 08.09. | Novo Nordisk's Wegovy helps free 40% of kids from obesity in phase 3 trial | ||
| 08.09. | FDA approves AstraZeneca's Etcamah, opening ctDNA-guided treatment paradigm in breast cancer | ||
| 08.09. | UCB turns to art for 'Expressing Epilepsy' awareness campaign | ||
| 08.09. | Roche sweeps neurology corporate reputation rankings once again | ||
| 04.09. | Ionis' 'breakthrough' Alexander disease approval establishes pillar of rare disease pipeline | ||
| 04.09. | Daiichi unit American Regent recalls 3 epinephrine batches on particulate, leakage concerns | ||
| 04.09. | The people who stayed with the problem | ||
| 04.09. | UCB's Bimzelx comes from out of the blue to claim August's top pharma ad spending spot | ||
| 03.09. | Fresenius unit dinged in FDA warning letter flagging 'complaint trend' from customers |